Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD

Hepatic steatosis and insulin resistance are associated with severity of fibrosis in non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C. However, clinical significance of steatosis and insulin resistance on fibrosis in chronic hepatitis B (CHB) is not well established. The aim was to investigate the relationship between insulin resistance, hepatic steatosis, and fibrosis in patients with CHB.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Hepatitis B Blood-Borne Infections Chronic Disease Communicable Diseases DNA Virus Infections Digestive System Diseases Disease Attributes Fatty Liver Fibrosis Hepadnaviridae Infections Hepatic Fibrosis Hepatitis Hepatitis B Hepatitis B, Chronic Hepatitis, Chronic Hepatitis, Viral, Human Infections Liver Cirrhosis Liver Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Virus Diseases

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul Metropolitan Government Seoul National University

Seoul, 156-707, South Korea

About this study

acoustic radiation force impulse elastography

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Chronic hepatitis B patients
With evidences of hepatic steatosis on ultrasonography or pathology

Exclusion criteria

significant alcohol consumption or other known liver diseases

Treatment and study plan

Primary outcomes

Insulin resistance and fibrosis indices

Time frame: one year

Measurement for insulin resistance and fibrosis index for hepatic fibrosis assessment

Sponsors and collaborators

Lead sponsor

Seoul National University Boramae Hospital

Other

Registry information

Official study title

Association Between Insulin Resistance and Hepatic Fibrosis in Combined Chronic Hepatitis B and Non-alcoholic Fatty Liver Disease

Important dates

Study start: 2013
Primary completion: 2022
Study completion: 2022
First posted: Jan 9, 2014
Registry last updated: Apr 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed